Abstract
Daptomycin, a novel cyclic lipopeptide antibiotic, exhibits rapid bactericidal activity in vitro against most clinically relevant gram-positive organisms, including drug-resistant pathogens. Herein we describe a patient in whom methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin was responsible for bacteremia and progressive vertebral osteomyelitis during daptomycin therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Bacteremia / drug therapy
-
Bacteremia / microbiology
-
Daptomycin / administration & dosage
-
Daptomycin / pharmacology*
-
Daptomycin / therapeutic use
-
Drug Resistance, Bacterial
-
Humans
-
Male
-
Methicillin Resistance*
-
Middle Aged
-
Osteomyelitis / drug therapy
-
Osteomyelitis / microbiology
-
Osteomyelitis / pathology*
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / microbiology
-
Staphylococcal Infections / pathology
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / pathogenicity
-
Thoracic Vertebrae / microbiology*
-
Thoracic Vertebrae / pathology
Substances
-
Anti-Bacterial Agents
-
Daptomycin